OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis

Nature

Volumn 397, Issue 6717, 1999, Pages 315-323

  Kong, Young Yun ^a   Yoshida, Hiroki ^a   Sarosi, Ildiko ^b   Tan, Hong Lin ^b   Timms, Emma ^b   Capparelli, Casey ^b   Morony, Sean ^b   Oliveira dos Santos, Antonio J ^a   Van, Gwyneth ^b   Itie, Annick ^a   Khoo, Wilson ^a   Wakeham, Andrew ^a   Dunstan, Colin R ^b   Lacey, David L ^b   Mak, Tak W ^a   Boyle, William J ^b   Penninger, Josef M ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; B LYMPHOCYTE; CELL DIFFERENTIATION; CELL MATURATION; DENDRITIC CELL; GENE DISRUPTION; HEMATOPOIESIS; LYMPH NODE; MORPHOGENESIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; ORGANOGENESIS; OSTEOCLAST; PEYER PATCH; PRIORITY JOURNAL; T LYMPHOCYTE;

ANIMALS; B-LYMPHOCYTES; BONE REMODELING; CARRIER PROTEINS; CELL DIFFERENTIATION; CELLS, CULTURED; CYTOKINES; DENDRITIC CELLS; EMBRYONIC AND FETAL DEVELOPMENT; FEMALE; GENE TARGETING; GROWTH SUBSTANCES; HEMATOPOIESIS, EXTRAMEDULLARY; HEMATOPOIETIC STEM CELLS; LEUKOPOIESIS; LYMPH NODES; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; MUTAGENESIS; OSTEOCLASTS; OSTEOGENESIS; OSTEOPETROSIS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; T-LYMPHOCYTES; THYMUS GLAND;

ANIMALIA;

EID: 0033611467     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/16852     Document Type: Article

References (50)

1. Felix, R., Hofstetter, W. & Cecchini, M. G. Recent developments in the understanding of the pathophysiology of osteopetrosis. Eur. J. Endocrinol. 134, 143-156 (1996).
2. Roodman, G. D. Advances in bone biology: the osteoclast. Endocr. Hev. 17, 308-332 (1996).
3. Manolagas, S. C. & Jilka, R. L. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. New Engl. J. Med. 332, 305-311 (1995).
4. Popoff, S. N. & Schneider, G. B. Animal models of osteopetrosis: the impact of recent molecular developments on novel strategies for therapeutic intervention. Mol. Med. Today 2, 349-358 (1996).
5. Teitelbaum, S. I. The osteoclast and osteoporosis. Mt Sinai J. Med. 63, 399-402 (1996).
6. Reddi, A. H. Bone morphogenesis and modeling: soluble signals sculpt osteosomes in the solid state. Cell 89, 159-161 (1997).
7. Mostov, K. & Werb, Z. Journey across the osteoclast. Science 276, 219-220 (1997).
8. Rosen, C J. & Kessenich, C. R. The pathophysiology and treatment of postmenopausal osteoporosis. An evidence-based approach to estrogen replacement therapy. Endocr. Metab. Clin. North Am. 26, 295-311 (1997).
9. Kanis, J. A. Bone and cancer: pathophysiology and treatment of metastases. Bone 17 (suppl.), 101-105 (1995).
10. Seitz, M. & Hunstein, W. Enhanced prostanoid release from monocytes of patients with rheumatoid arthritis and active systemic lupus erythematosus. Annu. Rheum. Dis. 44, 438-445 (1985).
11. Yoshida, H. et al. The murine mutation osteopetrosis in in the coding region of the macrophage colony stimulating factor gene. Nature 345, 442-444 (1990).
12. Wiktor-Jedrzejczak, W. et al. Total absence of colony-stimulating factor 1 in the macrophage-deficient osteopetrotic (op/op) mouse. Proc. Natl Acad. Sci. USA 87, 4828-4832 (1990).
13. Lagasse, E. & Weissman, I. L. Enforced expression of Bcl-2 in monocytes rescues macrophages and partially reverses osteopetrosis in op/op mice. Cell 89, 1021-1031 (1997).
14. Begg, S. K. et al. Delayed hematopoietic development in osteopetrotic (op/op) mice. J. Exp. Med. 177, 237-242 (1993).
15. Lacey, D. L. et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93, 165-176 (1998).
16. Yasuda, H. et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl Acad. Sci. USA 95, 3597-3602 (1998).
17. Anderson, D. M. et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390, 175-179 (1997).
18. Wong, B. R. et al. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J. Biol. Chem. 272, 25190-25194 (1997).
19. Wong, B. R. et al. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J. Exp. Med. 186, 2075-2080 (1997).
20. Grigoriadis, A. E. et al. c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 266, 443-448 (1994).
21. Soriano, P., Montgomery, C., Geske, R. & Bradley, A. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 64, 693-702 (1991).
22. Iotsova, V. et al. Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. Nature Med. 3, 1285-1289 (1997).
23. Franzoso, G. et al. Requirement for NF-kappaB in osteoclast and B-cell development. Genes Dev. 11, 3482-3496 (1997).
24. Kurihara, N. et al. Generation of osteoclasts from isolated heatopoietic progenitor cells. Blood 74, 1295-1302 (1989).
25. Kurihara, N., Chenu, C., Miller, M., Civin, C. & Roodman, G. D. Identification of committed mononuclear precursors for osteoclast-like cells formed in long term human marrow cultures. Endocrinology 126, 2733-2741 (1990).
26. Anderson, G., Moore, N. C., Owen, J. J. & Jenkinson, E. J. Cellular interactions in thymocyte development. Annu. Rev. Immunol. 14, 73-99 (1996).
27. von Boehmer, H. & Fehling, H. J. Structure and function of the pre-T cell receptor. Annu. Rev. Immunol. 15, 433-452 (1997).
28. + dendritic cells and tartrate-resistant acid phosphatase-positive osteoclast-like multinucleated giant cells from human monocytes. Blood 88, 4029-4039 (1996).
29. Steinman, R. M., Kaplan, G., Witmer, M. D. & Cohn, Z. A. Identification of a novel cell type in peripheral lymphoid organs of mice. V. Purification of spleen dendritic cells, new surface markers, and maintenance in vitro. J. Exp. Med. 149, 1-16 (1979).
30. Inaba, K. et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 176, 1693-1702 (1992).
31. Saoulli, K. et al. CD28-independent, TRAF2-dependent costimulation of resting T cells by 4-1BB ligand. J. Exp. med. 187, 1849-1862 (1998).
32. - T lymphocytes by 4-1BB ligand. J. Immunol. 158, 551-559 (1997).
33. De Togni, P. et al. Abnormal development of peripheral lymphoid organs in mice deficient in lymphotoxin. Science 264, 703-707 (1994).
34. Koni, P. A. et al. Distinct roles in lymphoid organogenesis for lymphotoxins alpha and beta revealed in lymphotoxin beta-deficient mice. Immunity 6, 491-500 (1997).
35. Alimzhanov, M. B. et al. Abnormal development of secondary lymphoid tissues in lymphotoxin beta-deficient mice. Proc. Natl Acad. Sci. USA 94, 9302-9307 (1997).
36. Matsumoto, M. et al. Role of lymphotoxin and the type I TNF receptor in the formation of germinal centers. Science 271, 1289-1291 (1996).
37. Pasparakis, M., Alexopoulou, L., Episkopou, V. & Kollias, G. Immune and inflammatory responses in TNF alpha-deficient mice: a critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J. Exp. Med. 184, 1397-1411 (1996).
38. Futterer, A., Mink, K., Luz, A., Kosco-Vilbois, M. H. & Pfeffer, K. The lymphotoxin β receptor controls organogenesis and affinity maturation in peripheral lymphoid tissues. Immunity 9, 59-70 (1998).
39. Rennert, P. D., James, D., Mackey, F., Browning, J. L. & Hochman, P. S. Lymph node genesis is induced by signaling through the lymphotoxin β receptor. Immunity 9, 71-79 (1998).
40. Bailey, R. P. & Weiss, L. Ontogeny of human fetal lymph nodes. Am. J. Anat. 142, 15-27 (1975).
41. Cheng, A. M. et al. The Syk and ZAP-70 SH2-containing tyrosine kinases are implicated in pre-T cell receptor signaling. Proc. Natl Acad. Sci. USA 94, 9797-9801 (1997).
42. Clements, J. L. et al. Requirement for the leukocyte-specific adapter protein SLP-76 for normal T cell development. Science 281, 416-419 (1998).
43. Fehling, H. J., Krotkova, A., Saint-Ruf, C. & von Boehmer, H. Crucial role of the pre-T-cell receptor alpha gene in development of alpha beta but not gamma delta T cells. Nature 375, 795-798 (1995).
44. Irving, B. A., Alt, F. W. & Killeen, N. Thymocyte development in the absence of pre-T cell receptor extracellular immunoglobulin domains. Science 280, 905-908 (1998).
45. Turner, M. et al. A requirement for the Rho-family GTP exchange factor Vav in positive and negative selection of thymocytes. Immunity 7, 451-460 (1997).
46. Peschon, J. J. et al. Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice. J. Exp. Med. 180, 1955-1960 (1994).
47. -1- mice. Cell 89, 1011-1019 (1997).
48. Mombaerts, P. et al. Spontaneous development of inflammatory bowel disease in T cell receptor mutant mice. Cell 75, 274-282 (1993).
49. Simonet, W. S. et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89, 309-319 (1997).
50. Takahashi, N. et al. Deficiency of osteoclasts in osteopetrotic mice is due to a defect in the local microenvironment provided by osteoblastic cells. Endocrinology 128, 1792-1796 (1991).